AngioDynamics secures FDA approval for RELIEF study of NanoKnife

AngioDynamics has received approval from the FDA for an IDE application to begin the RELIEF clinical trial of NanoKnife. The study will enrol up to 40 participants across a maximum of five clinical sites in the US. BPH can cause lower urinary tract symptoms such as frequency, urgency, weak stream, and incomplete bladder emptying. Credit: PanuShot / Shutterstock.com. AngioDynamics has received approval from the US Food and Drug Administration (FDA) for an investigational device exemption application to begin the RELIEF clinical trial of the NanoKnife system. The single-arm, prospective trial is set to evaluate the safety and effectiveness of irreversible…

Source: Medical Device Network